CNK-UT / ST Phi Therap, Zhejiang University - LARVOL DELTA

Safety and Efficiency of the Universal CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease Patients (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P1 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Universal CNK-UT Therapy for Refractory aGVHD (clinicaltrials.gov) - P1 | N=23 | Recruiting | Sponsor: First Affiliated Hospital of Zhejiang University

New P1 trial • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • REG3A

Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Zhejiang University

CAR T-Cell Therapy • Metastases • New P1 trial • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • IL2